Skip to content

Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.

Non-randomized Observational Study to Collate Data Regarding the Safety, Efficacy and Satisfaction of ReX® in the Management of Solid Oral Medications.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06335758
Acronym
RegStud
Enrollment
1000
Registered
2024-03-28
Start date
2024-01-15
Completion date
2026-01-31
Last updated
2024-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Any Solid Oral Medication

Keywords

Solid oral medication

Brief summary

The goal of this observational study is to evaluate the safety, efficacy and patient satisfaction with the ReX Remote Digital Nurse by patients receiving solid oral medication. The study will evaluate and monitor use of ReX in respect of: * treatment duration * adverse events * patient adherence and compliance * engagement with ReX via patient-reported outcomes Patients participating in the study will receive their normal medication as standard of care via ReX. Progress will be monitored via patients' responses to questions presented on the ReX touch screen.

Detailed description

The ReX platform is a class 1 FDA device listed under product code NXB Dispenser Solid Medication. It comprises: * Hand-held medication dispenser with touch screen (ReX Remote Digital Nurse). * Disposable cartridge pre-loaded with pills or capsules. The cartridge includes an integral mouthpiece. Patients inhale at the mouthpiece causing pills to be dispensed into the mouth. * Web application (ReX Treatment Manager) which collects data generated by the ReX hand-held dispenser. ReX manages and monitors medication-based therapy by means of: * Reminders to take pills. Reminders are sent to patients and caregivers by email, SMS or via the telephone support team. * Electronic patient recorded outcomes (ePROs) presented to patients via the dispenser touch screen. ePROs include questions, tips and reminders. * Notifications sent by email or SMS in the event of the patient exceeding a pre-defined threshold. In this study, following training, patients will be offered their standard oral medication via the ReX Remote Digital Nurse. They will receive cartridges pre-loaded with medication by the pharmacy. Safety, efficacy and patient satisfaction with the device are monitored over a 24-week period by phone calls and periodic questionnaires. Data collected by the ReX Remote Digital Nurse include: * medication name * prescribed dosage * doses taken per day * pills taken per dose * ePRO responses * missed pill intakes

Interventions

ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).

Sponsors

US Oncology Research
CollaboratorINDUSTRY
Dosentrx Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 18 years of age or older. 2. Care team recommends the use of ReX as a standard of care. 3. Patients have 5th grade reading level. 4. Patient was prescribed oral medication. 5. Patient takes medication at home.

Exclusion criteria

1. Patient has significant physical disability including poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent or use the ReX dispensing unit effectively. 2. Patient failed to pass the learning module during ReX onboarding flow. 3. Patient is at end stage or terminal illness with anticipated life expectancy of 6 months or less.

Design outcomes

Primary

MeasureTime frameDescription
Treatment duration24 weeksAt least 3 months while using ReX
Patient satisfaction24 weeksAt least 3.5 on a scale up to 5
Adverse events24 weeksNone related to use of ReX
Patient adherence24 weeksNo. of pills taken by patient as a percentage of pills prescribed \>80%
Patient compliance24 weeksNo. of pills taken as percentage of pills to be taken in alloted time frame \>70%
Patient engagement24 weeksNo. of questions answered as a percentage of questions asked \>70% of ePROs

Countries

United States

Contacts

Primary ContactNatan Paz
natan.p@dosentrx.com+972 52 6577126

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026